{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:18:35Z","timestamp":1783433915043,"version":"3.54.6"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to systematically identify systemic drugs associated with retinal artery occlusion (RAO) using real-world data from the US FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports from January 2004 to December 2024 were analyzed. Disproportionality analyses (ROR, PRR, BCPNN, and MGPS) were applied to detect signals of disproportionate reporting. Drugs were further evaluated based on signal strength and time-to-onset characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 626 drugs were initially screened, among which 36 drugs were identified as having significant disproportionality signals for RAO. These drugs were categorized into several pharmacological classes, including antineoplastic agents, anti-VEGF agents, reproductive system medications, anesthetics, anti-inflammatory drugs, hormonal agents, and others. Strong signals, as indicated by the BCPNN algorithm, were observed for mepivacaine, brolucizumab, and pegaptanib. Anesthetic agents exhibited the shortest median time to onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study characterizes the reporting patterns and signal strength of RAO across multiple drug classes using pharmacovigilance data. These findings provide real-world evidence to enhance clinical awareness and support safer prescribing practices, while emphasizing the need for further validation in controlled studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1851758","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:58:06Z","timestamp":1783432686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Signals of drug-related retinal artery occlusion: a multi-country retrospective study from a spontaneous reporting system"],"prefix":"10.3389","volume":"13","author":[{"given":"Xianfen","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First People\u2019s Hospital of Chenzhou","place":["Hunan, China"]},{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[{"name":"Ophthalmic Center, The Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinan","family":"Wu","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Xiamen University Affiliated Xiamen Eye Center, Fujian Engineering and Research Center of Eye Regenerative Medicine, School of Medicine, Eye Institute of Xiamen University, Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Wu","sequence":"additional","affiliation":[{"name":"The Affiliated Chenzhou Hospital of University of South China","place":["Hengyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First People\u2019s Hospital of Chenzhou","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulun","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First People\u2019s Hospital of Chenzhou","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1056\/NEJMicm2026957","article-title":"Central retinal artery and vein occlusion.","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000366","article-title":"Management of central retinal artery occlusion: a scientific statement from the American heart association.","volume":"52","author":"Mac Grory","year":"2021","journal-title":"Stroke."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","article-title":"Retinal vascular occlusions.","volume":"396","author":"Scott","year":"2020","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","article-title":"Risk of stroke, myocardial infarction, and death after retinal artery occlusion.","volume":"141","author":"Wai","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ophtha.2016.09.024","article-title":"Retinal and ophthalmic artery occlusions preferred practice pattern\u00ae.","volume":"124","author":"Olsen","year":"2017","journal-title":"Ophthalmology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ophtha.2021.07.017","article-title":"Stroke risk before and after central retinal artery occlusion: a population-based analysis.","volume":"129","author":"Chodnicki","year":"2022","journal-title":"Ophthalmology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00415-022-11439-7","article-title":"Thrombolysis in central retinal artery occlusion: a retrospective observational study.","volume":"270","author":"Raber","year":"2023","journal-title":"J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1111\/aos.14058","article-title":"Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections.","volume":"97","author":"Gao","year":"2019","journal-title":"Acta Ophthalmologica."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01221-z","article-title":"Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.","volume":"15","author":"Januzzi","year":"2022","journal-title":"J Hematol Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/neurintsurg-2020-016759","article-title":"Incidence and predictors of ophthalmic artery occlusion in intra-arterial chemotherapy for retinoblastoma.","volume":"13","author":"Sweid","year":"2021","journal-title":"J Neurointerv Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS.","volume":"118","author":"Potter","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.oret.2025.08.018","article-title":"Association of anti-VEGF therapy with reported ocular adverse events: a global pharmacovigilance analysis.","volume":"10","author":"Lakhani","year":"2026","journal-title":"Ophthalmol Retina."},{"key":"B13","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018.","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction.","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e233068","DOI":"10.1001\/jamanetworkopen.2023.3068","article-title":"Incidence of retinal artery occlusion and related mortality in korea, 2005 to 2018.","volume":"6","author":"Hwang","year":"2023","journal-title":"JAMA Netw Open."},{"key":"B18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/24741264251332515","article-title":"Intraocular inflammation, safety events, and outcomes after intravitreal injection of ranibizumab, aflibercept, brolucizumab, abicipar pegol, and faricimab for nAMD.","volume":"9","author":"Stevanovic","year":"2025","journal-title":"J Vitreoretin Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1755-3768.2008.01406.x","article-title":"Retinal artery occlusion following intravitreal anti-VEGF therapy.","volume":"88","author":"von Hanno","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajo.2024.01.016","article-title":"Systemic arterial and venous thrombotic events associated with anti-vascular endothelial growth factor injections: a meta-analysis.","volume":"262","author":"Jhaveri","year":"2024","journal-title":"Am J Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1167\/iovs.10-5842","article-title":"Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion.","volume":"52","author":"Sacu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab.","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1055\/s-0031-1273197","article-title":"[hemicentral retinal artery occlusion due to oral contraceptives].","volume":"228","author":"Schmidt","year":"2011","journal-title":"Klin Monbl Augenheilkd."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/24741264261442954","article-title":"Cilioretinal artery occlusion associated with subcutaneous testosterone replacement therapy.","author":"Andoh","year":"2026","journal-title":"J Vitreoretin Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s13256-023-04104-8","article-title":"Central retinal vein and artery occlusion associated with sildenafil: a case report and review of the literature.","volume":"17","author":"Torkashvand","year":"2023","journal-title":"J Med Case Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaophthalmol.2013.5047","article-title":"Acute, bilateral, concurrent central retinal artery occlusion in sickle cell disease after use of tadalafil (cialis).","volume":"131","author":"Murthy","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1167\/iovs.07-1208","article-title":"Sildenafil (viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition.","volume":"49","author":"Yuan","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/0310057X231215826","article-title":"Retinal artery occlusion after ophthalmic surgery under regional anaesthesia: a narrative review.","volume":"52","author":"Chua","year":"2024","journal-title":"Anaesth Intensive Care."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/s0886-3350(01)00797-0","article-title":"Effect of sub-tenon\u2019s and peribulbar anesthesia on intraocular pressure and ocular pulse amplitude.","volume":"27","author":"Pianka","year":"2001","journal-title":"J Cataract Refract Surg."},{"key":"B31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/s0002-9394(99)00066-5","article-title":"Effects of peribulbar anesthesia on ocular blood flow in patients undergoing cataract surgery.","volume":"127","author":"Findl","year":"1999","journal-title":"Am J Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/s0161-6420(88)33130-1","article-title":"Ocular complications associated with retrobulbar injections.","volume":"95","author":"Morgan","year":"1988","journal-title":"Ophthalmology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1055\/s-0040-1722270","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a narrative review.","volume":"47","author":"Simion","year":"2021","journal-title":"Semin Thromb Hemost."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.3748\/wjg.v12.i28.4602","article-title":"Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C.","volume":"12","author":"Goncalves","year":"2006","journal-title":"World J Gastroenterol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1136\/bjophthalmol-2021-319118","article-title":"Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy.","volume":"106","author":"Zhou","year":"2022","journal-title":"Br J Ophthalmol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/j.jcjo.2023.10.013","article-title":"Risk of ocular adverse events with aromatase inhibitors.","volume":"59","author":"Feng","year":"2024","journal-title":"Can J Ophthalmol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1097\/IOP.0000000000002804","article-title":"Central retinal artery occlusion following intralesional triamcinolone injection for IgG4-related orbital disease.","volume":"41","author":"Sanchez","year":"2025","journal-title":"Ophthalmic Plast Reconstr Surg."},{"key":"B39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13256-022-03518-0","article-title":"Iatrogenic central retinal artery occlusion following retrobulbar anesthesia with adrenaline for vitreoretinal surgery: a case report.","volume":"16","author":"Confalonieri","year":"2022","journal-title":"J Med Case Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"bcr2016218246","DOI":"10.1136\/bcr-2016-218246","article-title":"Central retinal artery occlusion in a 30-year-old woman taking tranexamic acid.","volume":"2017","author":"Wijetilleka","year":"2017","journal-title":"BMJ Case Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"102013","DOI":"10.1016\/j.ajoc.2024.102013","article-title":"Branch retinal artery occlusion in a 49-year-old woman taking phentermine.","volume":"35","author":"Liu","year":"2024","journal-title":"Am J Ophthalmol Case Rep."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1851758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:58:08Z","timestamp":1783432688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1851758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":41,"alternative-id":["10.3389\/fmed.2026.1851758"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1851758","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1851758"}}